“…Hence, our observations provide an explanation for the important question why p53 mutations rather than p53 deletions arise in tumors (Deppert, 2007;Soussi and Wiman, 2007). Consistent with this, it was found that chemotherapeutics, hypoxia and oncogene activation induce checkpoint activation, replicational arrest and selection for aberrant p53 (Hanahan and Weinberg, 2000;Janssens and Tschopp, 2006;Finkel et al, 2007;Marusyk and DeGregori, 2007;Kra¨mer, 2009;Viale et al, 2009).…”